About ChemoCentryx (NASDAQ:CCXI)
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900
Debt
Debt-to-Equity Ratio0.06%
Current Ratio5.46%
Quick Ratio5.46%
Price-To-Earnings
Trailing P/E Ratio30.06
Forward P/E Ratio-9.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$82.50 million
Price / Sales6.44
Cash Flow$0.3747 per share
Price / Cash28.88
Book Value$1.63 per share
Price / Book6.64
Profitability
EPS (Most Recent Fiscal Year)$0.36
Net IncomeN/A
Net MarginsN/A
Return on Equity35.06%
Return on Assets11.71%
Miscellaneous
Employees66
Outstanding Shares49,070,000
ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx (NASDAQ:CCXI) posted its quarterly earnings results on Friday, March, 9th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of ($0.22) by $1.02. The biopharmaceutical company had revenue of $56.30 million for the quarter, compared to analysts' expectations of $9.03 million. View ChemoCentryx's Earnings History.
What price target have analysts set for CCXI?
2 analysts have issued twelve-month price targets for ChemoCentryx's stock. Their forecasts range from $16.00 to $16.00. On average, they expect ChemoCentryx's share price to reach $16.00 in the next twelve months. View Analyst Ratings for ChemoCentryx.
What are Wall Street analysts saying about ChemoCentryx stock?
Here are some recent quotes from research analysts about ChemoCentryx stock:
- 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (3/15/2018)
- 2. Cowen Inc analysts commented, "ChemoCentryx reported Q2 financials, including a net loss of $9.2MM and a June 30." (8/8/2017)
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Intra-Cellular Therapies (ITCI), CytomX Therapeutics (CTMX), Athenex (ATNX), Zai Lab (ZLAB), Uniqure (QURE), MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Biohaven Pharmaceutical (BHVN), Assembly Biosciences (ASMB), Alder BioPharmaceuticals (ALDR), Flexion Therapeutics (FLXN), Inflarx (IFRX), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), ARMO BioSciences (ARMO), Mirati Therapeutics (MRTX) and Eagle Pharmaceuticals (EGRX).
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Dr. Thomas J. Schall, Founder, Chairman, CEO & Pres (Age 59)
- Ms. Susan M. Kanaya, Chief Financial & Admin. Officer, Exec. VP and Sec. (Age 55)
- Mr. William Fairey, Exec. VP & COO
- Dr. Markus J. Cappel Ph.D., Chief Bus. Officer and Treasurer (Age 57)
- Dr. Rajinder Singh Ph.D., Sr. VP of Research (Age 51)
Has ChemoCentryx been receiving favorable news coverage?
Media coverage about CCXI stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ChemoCentryx earned a coverage optimism score of 0.05 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.85 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of ChemoCentryx?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of CCXI stock can currently be purchased for approximately $10.82.
How big of a company is ChemoCentryx?
ChemoCentryx has a market capitalization of $530.95 million and generates $82.50 million in revenue each year. ChemoCentryx employs 66 workers across the globe.
How can I contact ChemoCentryx?
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]
MarketBeat Community Rating for ChemoCentryx (CCXI)
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
ChemoCentryx (NASDAQ:CCXI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for ChemoCentryx in the last 12 months. Their average twelve-month price target is $16.00, suggesting that the stock has a possible upside of 47.87%. The high price target for CCXI is $16.00 and the low price target for CCXI is $16.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $16.00 | $16.00 | N/A | N/A |
| Price Target Upside: | 47.87% upside | 22.89% upside | N/A | N/A |
ChemoCentryx (NASDAQ:CCXI) Consensus Price Target History
ChemoCentryx (NASDAQ:CCXI) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/13/2018 | JPMorgan Chase | Reiterated Rating | Overweight -> Overweight | $13.00 -> $16.00 | Medium |  |
| 8/8/2017 | Cowen | Reiterated Rating | Hold | | High | |
| 2/21/2017 | JMP Securities | Initiated Coverage | Mkt Outperform -> Outperform | | N/A | |
(Data available from 4/23/2016 forward)
ChemoCentryx (NASDAQ:CCXI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ChemoCentryx (NASDAQ CCXI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 48.24%
ChemoCentryx (NASDAQ CCXI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/1/2017 | Roger C Lucas | Director | Sell | 2,250 | $10.07 | $22,657.50 | 93,846 | |
| 7/13/2017 | Petrus Bekker | Insider | Sell | 76,013 | $9.95 | $756,329.35 | 65,963 | |
| 7/12/2017 | Petrus Bekker | Insider | Sell | 30,000 | $9.98 | $299,400.00 | 65,963 | |
| 7/11/2017 | Petrus Bekker | Insider | Sell | 30,000 | $9.78 | $293,400.00 | 65,963 | |
| 7/10/2017 | Petrus Bekker | Insider | Sell | 19,877 | $9.30 | $184,856.10 | 79,426 | |
| 6/30/2017 | Petrus Bekker | Insider | Sell | 65,509 | $9.17 | $600,717.53 | 89,839 | |
| 5/1/2017 | Roger C Lucas | Director | Sell | 4,000 | $7.31 | $29,240.00 | 62,822 | |
| 1/3/2017 | Markus J Cappel | Insider | Sell | 26,821 | $7.51 | $201,425.71 | 20,833 | |
| 12/16/2016 | Petrus Bekker | Insider | Sell | 8,712 | $8.74 | $76,142.88 | 55,638 | |
| 12/5/2016 | Petrus Bekker | Insider | Sell | 30,000 | $8.50 | $255,000.00 | 83,594 | |
| 11/22/2016 | Petrus Bekker | Insider | Sell | 1,250 | $8.30 | $10,375.00 | 54,844 | |
| 11/11/2016 | Petrus Bekker | Insider | Sell | 33,332 | $8.00 | $266,656.00 | 54,228 | |
| 9/1/2016 | Roger C Lucas | Director | Sell | 4,000 | $5.07 | $20,280.00 | 74,822 | |
| 5/23/2016 | James L Tyree | Director | Sell | 5,544 | $4.39 | $24,338.16 | 26,119 | |
| 5/17/2016 | Thomas A Edwards | Director | Buy | 50,000 | $4.05 | $202,500.00 | 91,977 | |
| 5/16/2016 | Thomas A Edwards | Director | Buy | 25,000 | $4.05 | $101,250.00 | 41,977 | |
| 5/13/2016 | Geoffrey M Parker | Director | Buy | 40,000 | $4.03 | $161,200.00 | 13,514 | |
| 1/22/2016 | Susan M. Kanaya | CFO | Sell | 25,764 | $4.04 | $104,086.56 | | |
| 1/20/2016 | Susan M. Kanaya | CFO | Sell | 14,971 | $4.10 | $61,381.10 | | |
| 1/19/2016 | Susan M. Kanaya | CFO | Sell | 6,134 | $4.05 | $24,842.70 | | |
| 1/15/2016 | Susan M. Kanaya | CFO | Sell | 300 | $4.00 | $1,200.00 | | |
| 1/11/2016 | Geoffrey M Parker | Director | Buy | 20,000 | $4.63 | $92,600.00 | 13,514 | |
| 1/8/2016 | Susan M. Kanaya | CFO | Sell | 10,224 | $5.12 | $52,346.88 | | |
| 1/6/2016 | Susan M. Kanaya | CFO | Sell | 47,607 | $6.98 | $332,296.86 | | |
| 1/5/2016 | Susan M. Kanaya | CFO | Sell | 34,341 | $6.90 | $236,952.90 | | |
| 1/4/2016 | Susan M. Kanaya | CFO | Sell | 10,490 | $7.38 | $77,416.20 | | |
| 12/11/2015 | Geoffrey M Parker | Director | Buy | 20,000 | $7.25 | $145,000.00 | 13,514 | |
| 11/4/2015 | Value Fund L P Biotechnology | Insider | Sell | 360,000 | $7.00 | $2,520,000.00 | | |
| 11/2/2015 | Value Fund L P Biotechnology | Insider | Sell | 50,000 | $6.97 | $348,500.00 | | |
| 6/10/2015 | Bvf Partners L P/Il | Major Shareholder | Sell | 955,700 | $9.00 | $8,601,300.00 | | |
| 5/22/2015 | Ira Klein | Director | Sell | 10,811 | $7.44 | $80,433.84 | | |
| 4/1/2015 | Thomas J Schall | CEO | Sell | 24,267 | $7.50 | $182,002.50 | | |
| 3/31/2015 | Thomas J Schall | CEO | Sell | 16,540 | $7.55 | $124,877.00 | | |
| 3/30/2015 | Thomas J Schall | CEO | Sell | 1,200 | $7.51 | $9,012.00 | | |
| 3/24/2015 | Thomas J Schall | CEO | Sell | 50,371 | $7.84 | $394,908.64 | | |
| 3/19/2015 | Thomas J Schall | CEO | Sell | 18,146 | $8.34 | $151,337.64 | | |
| 3/17/2015 | Thomas J Schall | CEO | Sell | 31,316 | $8.55 | $267,751.80 | | |
| 3/9/2015 | Markus J Cappel | Treasurer | Sell | 34,125 | $7.81 | $266,516.25 | | |
| 3/4/2015 | Markus J Cappel | Treasurer | Sell | 40,875 | $7.98 | $326,182.50 | | |
| 3/3/2015 | Markus J Cappel | Treasurer | Sell | 5,943 | $7.81 | $46,414.83 | | |
| 3/2/2015 | Markus J Cappel | Treasurer | Sell | 14,390 | $8.13 | $116,990.70 | | |
| 11/18/2014 | Anne-Marie Duliege | EVP | Sell | 4,970 | $4.71 | $23,408.70 | | |
| 5/1/2014 | Thomas J Schall | CEO | Sell | 27,726 | $5.59 | $154,988.34 | | |
| 4/29/2014 | Thomas J Schall | CEO | Sell | 32,274 | $5.38 | $173,634.12 | | |
| 4/22/2014 | Markus J Cappel | Treasurer | Sell | 20,962 | $8.17 | $171,259.54 | | |
| 3/17/2014 | Thomas J Schall | CEO | Sell | 20,000 | $7.25 | $145,000.00 | | |
| 12/6/2013 | Geoffrey M Parker | Director | Buy | 20,000 | $5.15 | $103,000.00 | | |
| 12/5/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 189,800 | $5.01 | $950,898.00 | | |
| 11/6/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 136,066 | $4.92 | $669,444.72 | | |
| 11/1/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 336,225 | $4.99 | $1,677,762.75 | | |
| 10/9/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 1,289,354 | $5.34 | $6,885,150.36 | | |
| 10/3/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 109,425 | $5.49 | $600,743.25 | | |
| 9/13/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 325,635 | $5.95 | $1,937,528.25 | | |
| 9/13/2013 | Joseph M Feczko | Director | Buy | 10,000 | $6.03 | $60,300.00 | | |
| 8/13/2013 | Markus J Cappel | Treasurer | Sell | 5,459 | $12.90 | $70,421.10 | | |
| 8/7/2013 | Petrus Bekker | SVP | Sell | 5,000 | $13.26 | $66,300.00 | | |
| 8/5/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.42 | $67,100.00 | | |
| 8/1/2013 | Markus J Cappel | Treasurer | Sell | 6,250 | $13.82 | $86,375.00 | | |
| 7/17/2013 | Markus J Cappel | Treasurer | Sell | 5,459 | $14.52 | $79,264.68 | | |
| 7/17/2013 | Petrus Bekker | SVP | Sell | 10,000 | $14.54 | $145,400.00 | | |
| 7/16/2013 | Thomas J Schall | CEO | Sell | 22,089 | $14.39 | $317,860.71 | | |
| 7/3/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.43 | $67,150.00 | | |
| 7/2/2013 | Markus J Cappel | Treasurer | Sell | 6,250 | $13.88 | $86,750.00 | | |
| 6/28/2013 | Susan M Kanaya | CFO | Sell | 36,942 | $14.31 | $528,640.02 | | |
| 6/27/2013 | Petrus Bekker | SVP | Sell | 5,000 | $14.00 | $70,000.00 | | |
| 6/21/2013 | Markus J Cappel | Treasurer | Sell | 6,250 | $13.00 | $81,250.00 | | |
| 6/18/2013 | Markus J Cappel | Treasurer | Sell | 1,783 | $12.47 | $22,234.01 | | |
| 6/17/2013 | Petrus Bekker | SVP | Sell | 5,000 | $12.00 | $60,000.00 | | |
| 6/3/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.32 | $66,600.00 | | |
| 5/30/2013 | Susan M Kanaya | CFO | Sell | 12,770 | $14.28 | $182,355.60 | | |
| 5/28/2013 | Markus J Cappel | Treasurer | Sell | 3,676 | $14.10 | $51,831.60 | | |
| 5/24/2013 | Petrus Bekker | SVP | Sell | 4,800 | $14.00 | $67,200.00 | | |
| 5/17/2013 | Petrus Bekker | SVP | Sell | 15,000 | $13.97 | $209,550.00 | | |
| 5/15/2013 | Markus J Cappel | Treasurer | Sell | 15,668 | $14.08 | $220,605.44 | | |
| 5/15/2013 | Roger C Lucas | Director | Sell | 5,000 | $14.11 | $70,550.00 | | |
| 5/15/2013 | Thomas J Schall | CEO | Sell | 7,600 | $14.04 | $106,704.00 | | |
| 4/11/2013 | Markus J Cappel | Treasurer | Sell | 1,500 | $14.10 | $21,150.00 | | |
| 4/11/2013 | Petrus Bekker | SVP | Sell | 3,979 | $14.03 | $55,825.37 | | |
| 4/11/2013 | Thomas J Schall | CEO | Sell | 2,529 | $14.02 | $35,456.58 | | |
| 3/6/2013 | Petrus Bekker | SVP | Sell | 11,502 | $13.98 | $160,797.96 | | |
| 3/6/2013 | Thomas J Schall | CEO | Sell | 5,541 | $14.01 | $77,629.41 | | |
| 3/4/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.87 | $69,350.00 | | |
| 2/26/2013 | Juan C Jaen | SVP | Sell | 22,500 | $12.23 | $275,175.00 | | |
| 2/22/2013 | Thomas J Schall | CEO | Sell | 7,500 | $12.06 | $90,450.00 | | |
| 2/6/2013 | Roger C Lucas | Director | Sell | 3,857 | $11.52 | $44,432.64 | | |
| 2/4/2013 | Juan C Jaen | SVP | Sell | 3,875 | $11.69 | $45,298.75 | | |
| 1/17/2013 | Markus J Cappel | Treasurer | Sell | 2,700 | $11.16 | $30,132.00 | | |
| 11/6/2012 | Bvf Partners L P/Il | Major Shareholder | Buy | 40,000 | $12.00 | $480,000.00 | | |
| 10/4/2012 | Roger C Lucas | Director | Sell | 1,893 | $11.47 | $21,712.71 | | |
| 10/1/2012 | Susan M Kanaya | CFO | Sell | 3,971 | $11.89 | $47,215.19 | | |
| 10/1/2012 | Thomas J Schall | CEO | Sell | 15,000 | $11.53 | $172,950.00 | | |
(Data available from 1/1/2013 forward)
ChemoCentryx (NASDAQ CCXI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Free Research Report as ChemoCentryx’s Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y
finance.yahoo.com - April 19 at 8:12 AM |
 | ChemoCentryx (CCXI) Upgraded at TheStreet
www.americanbankingnews.com - April 18 at 10:41 AM |
| ChemoCentryx (CCXI) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 9:56 AM |
| ChemoCentryx (CCXI) Downgraded to Hold at ValuEngine
www.americanbankingnews.com - April 17 at 11:37 AM |
| Zacks: ChemoCentryx (CCXI) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 16 at 5:19 PM |
| ChemoCentryx (CCXI) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 14 at 7:41 AM |
| ChemoCentryx (CCXI) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 7:21 AM |
| Should You Be Tempted To Sell ChemoCentryx Inc (NASDAQ:CCXI) At Its Current PE Ratio?
finance.yahoo.com - April 13 at 8:16 AM |
| ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
finance.yahoo.com - April 11 at 5:35 PM |
| Recent Analysis Shows Ericsson, Toronto Dominion Bank, Odonate Therapeutics, Colliers International Group, ChemoCentryx, and CyberArk Software Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 10 at 8:20 AM |
| Can ChemoCentryx Inc (NASDAQ:CCXI) Continue To Outperform Its Industry?
finance.yahoo.com - April 4 at 4:16 PM |
 | Active-Investors: Wired News - Exelixis' Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX
www.finanznachrichten.de - April 2 at 8:33 AM |
| Wired News – Exelixis’ Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX
finance.yahoo.com - April 2 at 8:33 AM |
| ChemoCentryx Inc (CCXI) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - March 28 at 9:59 AM |
 | ChemoCentryx: Significant Progress In Recent Months
seekingalpha.com - March 24 at 5:18 PM |
 | ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 ...
globenewswire.com - March 24 at 5:18 PM |
| ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
finance.yahoo.com - March 22 at 5:38 PM |
| Edited Transcript of CCXI earnings conference call or presentation 9-Mar-18 1:30pm GMT
finance.yahoo.com - March 18 at 8:14 AM |
| ChemoCentryx (CCXI) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 15 at 7:06 PM |
| ChemoCentryx (CCXI) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - March 15 at 12:28 AM |
| ChemoCentryx (CCXI) Upgraded at BidaskClub
www.americanbankingnews.com - March 14 at 7:51 PM |
| ChemoCentryx (CCXI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 14 at 7:17 PM |
| ChemoCentryx Inc (CCXI) Given $13.00 Consensus Price Target by Analysts
www.americanbankingnews.com - March 13 at 9:26 PM |
| ChemoCentryx (CCXI) PT Raised to $16.00 at JPMorgan Chase & Co.
www.americanbankingnews.com - March 13 at 3:55 PM |
| ChemoCentryx (CCXI) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - March 11 at 8:12 AM |
| ChemoCentryx (CCXI) Releases Earnings Results, Beats Estimates By $1.02 EPS
www.americanbankingnews.com - March 10 at 9:36 AM |
| ChemoCentryx's (CCXI) CEO Tom Schall on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 10 at 8:18 AM |
| ChemoCentryx Inc (NASDAQ:CCXI): When Will It Breakeven?
finance.yahoo.com - March 9 at 6:55 PM |
| ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 9 at 8:16 AM |
| Chemocentryx, Inc. to Host Earnings Call
finance.yahoo.com - March 9 at 8:16 AM |
| ChemoCentryx posts 4Q profit
finance.yahoo.com - March 9 at 8:16 AM |
| ChemoCentryx beats by $1.00, beats on revenue
seekingalpha.com - March 9 at 7:14 AM |
 | Form 4 ChemoCentryx, Inc. For: Mar 05 Filed by: Schall Thomas J.
www.streetinsider.com - March 8 at 8:19 AM |
| ChemoCentryx to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 5:43 PM |
| ChemoCentryx (CCXI) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 3 at 6:10 PM |
| ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018
finance.yahoo.com - March 1 at 5:54 PM |
 | ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018
feeds.benzinga.com - March 1 at 8:46 AM |
| Zacks: ChemoCentryx Inc (CCXI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 26 at 5:34 AM |
| Zacks: Analysts Set $13.00 Target Price for ChemoCentryx Inc (CCXI)
www.americanbankingnews.com - February 4 at 5:16 AM |
| ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer
finance.yahoo.com - January 23 at 5:28 PM |
| ChemoCentryx (CCXI) & Ocera Therapeutics (OCRX) Financial Review
www.americanbankingnews.com - January 16 at 7:56 PM |
| Head to Head Review: Argos Therapeutics (ARGS) vs. ChemoCentryx (CCXI)
www.americanbankingnews.com - January 12 at 3:16 AM |
| ChemoCentryx Inc (CCXI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 5 at 8:06 AM |
| Here's Why ChemoCentryx Rose as Much as 53.5% Today
finance.yahoo.com - January 4 at 5:33 PM |
 | Here's Why ChemoCentryx Rose as Much as 53.5% Today
www.fool.com - January 4 at 2:11 PM |
| Vifor Pharma Ltd.: AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY
www.finanznachrichten.de - January 4 at 9:15 AM |
 | BRIEF-ChemoCentryx Says EMA Accepts Vasculitis Drug Avacopan For Conditional Review
www.reuters.com - January 4 at 9:15 AM |
| ETFs with exposure to ChemoCentryx, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 12:35 PM |
| ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 5:06 PM |
| Should You Buy ChemoCentryx Inc (CCXI) Now?
finance.yahoo.com - November 27 at 6:20 PM |
ChemoCentryx (NASDAQ:CCXI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ChemoCentryx (NASDAQ:CCXI) Income Statement, Balance Sheet and Cash Flow Statement
ChemoCentryx (NASDAQ CCXI) Stock Chart for Monday, April, 23, 2018
Loading chart…
